Cipla’s arm inks agreement with Avenue Therapeutics
InvaGen Pharmaceuticals Inc., a subsidiary of the leading global pharmaceutical company Cipla, has entered into definitive agreements with two closing stages for a proposed acquisition of Avenue Therapeutics, Inc., a Fortress Biotech company focused on the development and commercialization of intravenous (IV) Tramadol. At the first stage closing, InvaGen or its affiliates will acquire, through … Read more
